AAP
BDTX icon

Arax Advisory Partners’s Black Diamond Therapeutics BDTX Stock Holding History

Arax Advisory Partners’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17 Sell
9
-83
-90% -$203 ﹤0.01% 5180
2026
Q1 		$43 Buy
92
+72
+360% +$171 ﹤0.01% 3670
2025
Q4 		$49 Sell
20
-46
-70% -$163 ﹤0.01% 3919
2025
Q3 		$250 Buy
+66
New +$193 ﹤0.01% 3432

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Arax Advisory Partners's BDTX Position: Q2 2026 in Review

Arax Advisory Partners reduced its Black Diamond Therapeutics (BDTX) stake by 90% in Q2 2026, selling an estimated $203 and leaving 9 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #5180.

Arax Advisory Partners first reported a position in BDTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $250 in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Arax Advisory Partners held 9 shares of Black Diamond Therapeutics worth $17 as of Q2 2026.
  • Arax Advisory Partners sold 83 Black Diamond Therapeutics shares in Q2 2026, an estimated $203.
  • Black Diamond Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5180 holding.
  • Arax Advisory Partners first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Black Diamond Therapeutics position peaked at $250 in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.